Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: aPost HocAnalysis of the PRODIGE-GERCOR IDEA-France Trial

Purpose: Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage-III colon cancer. We analyzed ctDNA of patients randomized in the phase III IDEA-France trial. Experimental Design: ctDNA was tested for WIF1 and NPY by droplet digital PCR with method developed and validated for colorectal cancer. Disease-free survival (DFS) and overall survival (OS) were analyzed via multivariable analysis in patients with...